The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

Russell Wooten of Hendersonville, North Carolina, has spent much of his life struggling with obesity, often carrying 260 pounds on his 6-foot-3 frame. He repeatedly starved himself to lose weight, ...

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.

An anxious generation turns to functional foods and beverages and alternative medicine, inspiring better-for-you innovation.

The conversation surrounding healthcare reform has intensified in recent years, revealing deep divides in how we view ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...